LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

The market value of the company surpassed the size of Denmark’s entire economy last year and, for a period, Novo Nordisk was ...

Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Donald Trump has a lot of thoughts. Most of them don't make any sense, and the sentences themselves are often barely ...